2. Academic Validation
  3. Irisin-Encapsulated Mitochondria-Targeted Biomimetic Nanotherapeutics for Alleviating Acute Kidney Injury

Irisin-Encapsulated Mitochondria-Targeted Biomimetic Nanotherapeutics for Alleviating Acute Kidney Injury

  • Adv Sci (Weinh). 2024 Aug 9:e2402805. doi: 10.1002/advs.202402805.
Xia Zhang 1 2 3,  Lijia Liang 2 4 5,  Fengxian Wang 1 2 4,  Pedro A Jose 6,  Ken Chen 1 2 3,  Chunyu Zeng 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042, P. R. China.
  • 2 Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China, Chongqing, 400042, P. R. China.
  • 3 Chongqing Key Laboratory for Hypertension Research, Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing, 400042, P. R. China.
  • 4 Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, 400714, P. R. China.
  • 5 Chongqing General Hospital, Chongqing, 401147, P. R. China.
  • 6 Division of Renal Diseases & Hypertension, Department of Medicine and Pharmacology-Physiology, The George Washington University School of Medicine & Health Sciences, Washington DC, 20037, USA.
PMID: 39119832 DOI: 10.1002/advs.202402805
Abstract

Acute kidney injury (AKI) is the sudden decrease in renal function that can be attributed to dysregulated Reactive Oxygen Species (ROS) production and impaired mitochondrial function. Irisin, a type I membrane protein secreted by skeletal muscles in response to physical activity, has been reported to alleviate kidney damage through regulation of mitochondrial biogenesis and oxidative metabolism. In this study, a macrophage membrane-coated metal-organic framework (MCM@MOF) is developed as a nanocarrier for encapsulating irisin to overcome the inherent characteristics of irisin, including a short circulation time, limited kidney-targeting ability, and low membrane permeability. The engineered irisin-mediated biomimetic nanotherapeutics have extended circulation time and enhanced targeting capability toward injured kidneys due to the preservation of macrophage membrane proteins. The irisin-encapsulated biomimetic nanotherapeutics effectively mitigate acute ischemia-reperfusion injury by protecting mitochondrial function and modulating SOD2 levels in renal tubular epithelial cells. The present study provides novel insights to advance the development of irisin as a potential therapeutic approach for AKI.

Keywords

acute kidney injury; biomimetic nanocarriers; irisin; mitochondria.

Figures
Products